|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
48,973,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Arcellx is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Co.'s D-Domain powered autologous and allogeneic Chimeric Antigen Receptor T cells (CAR-Ts), including classical single infusion CAR-Ts product candidate, CART-ddBCMA, is for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM), defined as patients with either minimal response or disease progression within 60 days of last treatment. Co. is also developing its ARC-SparX programs, ACLX-001 in r/r MM and ACLX-002 and ACLX-003 in r/r acute myeloid leukemia and myelodysplastic syndrome.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
312,500 |
| Total Buy Value |
$0 |
$0 |
$0 |
$5,000,000 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
647,567 |
1,317,015 |
3,339,186 |
3,438,046 |
| Total Sell Value |
$45,084,544 |
$78,376,547 |
$168,163,435 |
$171,480,149 |
| Total People Sold |
5 |
5 |
6 |
10 |
| Total Sell Transactions |
13 |
18 |
31 |
44 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Heery Christopher |
CHIEF MEDICAL OFFICER |
• – – |
2024-03-26 |
4 |
AS |
$68.55 |
$376,648 |
D/D |
(5,450) |
8,938 |
|
- |
|
| Heery Christopher |
CHIEF MEDICAL OFFICER |
• – – |
2024-03-26 |
4 |
OE |
$6.28 |
$34,226 |
D/D |
5,450 |
14,388 |
|
- |
|
| Heery Christopher |
CHIEF MEDICAL OFFICER |
• – – |
2024-03-22 |
4 |
AS |
$69.59 |
$2,903,066 |
D/D |
(41,365) |
8,938 |
|
- |
|
| Heery Christopher |
CHIEF MEDICAL OFFICER |
• – – |
2024-03-22 |
4 |
OE |
$6.28 |
$125,600 |
D/D |
20,000 |
50,303 |
|
- |
|
| Carroll Jill |
|
– • – |
2024-03-21 |
4 |
S |
$70.55 |
$35,575,755 |
I/I |
(504,263) |
1,479,148 |
|
- |
|
| Gilson Michelle |
CHIEF FINANCIAL OFFICER |
• – – |
2024-03-18 |
4 |
AS |
$69.03 |
$473,255 |
D/D |
(6,825) |
9,485 |
|
- |
|
| Ware Olivia C |
|
– • – |
2024-03-15 |
4 |
AS |
$69.44 |
$633,582 |
D/D |
(9,000) |
0 |
|
- |
|
| Ware Olivia C |
|
– • – |
2024-03-15 |
4 |
OE |
$7.61 |
$68,490 |
D/D |
9,000 |
9,000 |
|
- |
|
| Heery Christopher |
CHIEF MEDICAL OFFICER |
• – – |
2024-02-12 |
4 |
S |
$64.46 |
$191,251 |
D/D |
(2,967) |
30,303 |
|
- |
|
| Elghandour Rami |
SEE REMARKS |
• • – |
2024-02-12 |
4 |
S |
$64.46 |
$719,948 |
D/D |
(11,169) |
92,339 |
|
- |
|
| Heery Christopher |
CHIEF MEDICAL OFFICER |
• – – |
2024-02-09 |
4 |
S |
$63.40 |
$233,811 |
D/D |
(3,688) |
33,270 |
|
- |
|
| Elghandour Rami |
SEE REMARKS |
• • – |
2024-02-09 |
4 |
S |
$63.40 |
$880,340 |
D/D |
(13,886) |
103,508 |
|
- |
|
| Heery Christopher |
CHIEF MEDICAL OFFICER |
• – – |
2024-02-08 |
4 |
S |
$62.29 |
$215,290 |
D/D |
(3,456) |
36,958 |
|
- |
|
| Elghandour Rami |
SEE REMARKS |
• • – |
2024-02-08 |
4 |
S |
$62.29 |
$810,451 |
D/D |
(13,010) |
117,394 |
|
- |
|
| Heery Christopher |
CHIEF MEDICAL OFFICER |
• – – |
2024-02-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,555 |
40,414 |
|
- |
|
| Elghandour Rami |
SEE REMARKS |
• • – |
2024-02-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
70,211 |
130,404 |
|
- |
|
| Gilson Michelle |
Chief Financial Officer |
• – – |
2024-01-04 |
4 |
S |
$55.27 |
$470,551 |
D/D |
(8,514) |
16,310 |
|
- |
|
| Heery Christopher |
Chief Medical Officer |
• – – |
2024-01-04 |
4 |
S |
$55.27 |
$419,926 |
D/D |
(7,598) |
17,859 |
|
- |
|
| Elghandour Rami |
See Remarks |
• • – |
2024-01-04 |
4 |
S |
$55.27 |
$1,606,804 |
D/D |
(29,073) |
60,193 |
|
- |
|
| Heery Christopher |
Chief Medical Officer |
• – – |
2024-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,519 |
25,457 |
|
- |
|
| Elghandour Rami |
See Remarks |
• • – |
2024-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
53,097 |
89,266 |
|
- |
|
| Gilead Sciences Inc |
10% Owner |
– – • |
2023-12-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,720,803 |
|
- |
|
| Heery Christopher |
Chief Medical Officer |
• – – |
2023-12-18 |
4 |
S |
$50.06 |
$6,020,281 |
D/D |
(120,000) |
7,795 |
|
- |
|
| Heery Christopher |
Chief Medical Officer |
• – – |
2023-12-18 |
4 |
OE |
$6.28 |
$753,600 |
D/D |
120,000 |
127,795 |
|
- |
|
| Carroll Jill |
Director |
– • – |
2023-12-14 |
4 |
S |
$49.13 |
$24,774,441 |
I/I |
(504,263) |
1,983,411 |
|
- |
|
84 Records found
|
|
Page 1 of 4 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
